SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)

NCT05303519 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

365

Enrollment

INDUSTRY

Sponsor class

Conditions

Glioma
Astrocytoma, Grade IV
IDH1-mutant Glioma
Astrocytoma, IDH-Mutant, Grade 3
Astrocytoma, IDH-Mutant, Grade 4
Astrocytoma, IDH-Mutant, Grade 2
Oligodendroglioma
Oligodendroglioma, IDH-Mutant and 1p/19q-Codeleted

Interventions

DRUG: safusidenib
DRUG: Placebo

Sponsor

Nuvation Bio Inc.

Collaborators

[object Object]